PMID- 20531305
OWN - NLM
STAT- MEDLINE
DCOM- 20101007
LR  - 20220408
IS  - 1476-5594 (Electronic)
IS  - 0950-9232 (Print)
IS  - 0950-9232 (Linking)
VI  - 29
IP  - 34
DP  - 2010 Aug 26
TI  - EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war 
      on cancer.
PG  - 4741-51
LID - 10.1038/onc.2010.215 [doi]
AB  - Tumors are cellularly and molecularly heterogeneous, with subsets of 
      undifferentiated cancer cells exhibiting stem cell-like features (CSCs). 
      Epithelial to mesenchymal transitions (EMT) are transdifferentiation programs 
      that are required for tissue morphogenesis during embryonic development. The EMT 
      process can be regulated by a diverse array of cytokines and growth factors, such 
      as transforming growth factor (TGF)-beta, whose activities are dysregulated 
      during malignant tumor progression. Thus, EMT induction in cancer cells results 
      in the acquisition of invasive and metastatic properties. Recent reports indicate 
      that the emergence of CSCs occurs in part as a result of EMT, for example, 
      through cues from tumor stromal components. Recent evidence now indicates that 
      EMT of tumor cells not only causes increased metastasis, but also contributes to 
      drug resistance. In this review, we will provide potential mechanistic 
      explanations for the association between EMT induction and the emergence of CSCs. 
      We will also highlight recent studies implicating the function of 
      TGF-beta-regulated noncoding RNAs in driving EMT and promoting CSC self-renewal. 
      Finally we will discuss how EMT and CSCs may contribute to drug resistance, as 
      well as therapeutic strategies to overcome this clinically.
FAU - Singh, A
AU  - Singh A
AD  - Massachusetts General Hospital Cancer Center and Harvard Medical School, 
      Charlestown, MA, USA.
FAU - Settleman, J
AU  - Settleman J
LA  - eng
GR  - K99 CA149169/CA/NCI NIH HHS/United States
GR  - K99 CA149169-01/CA/NCI NIH HHS/United States
GR  - K99 CA149169-02/CA/NCI NIH HHS/United States
GR  - R00 CA149169/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20100607
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
SB  - IM
MH  - Animals
MH  - Drug Resistance, Neoplasm
MH  - Epithelial Cells/pathology
MH  - Humans
MH  - Mesoderm/pathology
MH  - Neoplasms/*drug therapy/*pathology
MH  - Neoplastic Stem Cells/*pathology
PMC - PMC3176718
MID - NIHMS323987
EDAT- 2010/06/10 06:00
MHDA- 2010/10/12 06:00
PMCR- 2011/09/20
CRDT- 2010/06/10 06:00
PHST- 2010/06/10 06:00 [entrez]
PHST- 2010/06/10 06:00 [pubmed]
PHST- 2010/10/12 06:00 [medline]
PHST- 2011/09/20 00:00 [pmc-release]
AID - onc2010215 [pii]
AID - 10.1038/onc.2010.215 [doi]
PST - ppublish
SO  - Oncogene. 2010 Aug 26;29(34):4741-51. doi: 10.1038/onc.2010.215. Epub 2010 Jun 7.